The World Needs A New Anti-micro-biotic Technological Platform
Today, I have read approximately 10 articles on Antibiotics. I have concluded that with the recent executive action by The President, coupled with the outcries of various social-political organizations, that significant change to the utilization of antibiotic's with regard to agriculture, livestock and humans is optimally desirable. The bipartisan political will is certainly present. Yet, there does not appear to be a widely known technological platform that offers an accretive antimicrobacterial alternative that could be presented as an accretive choice for any one of the three mentioned industries. It would be a sublime master stroke of providence, if one biotechnology compound could be found that would trilaterally become the dream come true blockbuster for each of the respective three industries.
In short whether its household disinfectants with Proctor and Gamble(NYSE:PG), or agricultural with Monsanto (NYSE:MON), Dow Chemical (NYSE:DOW) or livestock, and companion animal with Zoetis (NYSE:ZTS), there is not a solution from the major companies mentioned that meets the winds of public demand and the Palm tree of political will.
However scientists at the University of Pennsylvania, did create such a sterling technological platform. The lead representative Brilacidin has completed its FDA 2b study, and now awaits the release of meaningfully structured data. From all interim bits of news, those in the realm of interested followers are optimistic that Brilacidin and also its preclinical sister compounds will prove to be the Holy Grail, that will eventually trilaterally combat antibacterial resistant bugs, and also fungus' in people, agriculture, and livestock.
THE BELOW WRITTEN BY KAREN LO ASSOC ED OF THE MEAL
The Food and Drug Administration has reported that the amount of antibiotics being given to farm animals in the United States is at an all-time high, increasing by 16 percent between 2009 and 2012, according to The Atlantic.
Nearly 70 percent of the antibiotics commonly used on animals are considered "medically important" for humans, a further 80 percent of which are being used to ensure more rapid growth and disease prevention for farm animals.Related Articles
- 16 Organizations Working to Raise Antibiotic Resistance Awareness
- Another Step is Taken in Banning Antibiotics From Farming
- Antibiotic-Resistant Bacteria in Meat on the Rise
- Beyond the Label: What 'Raised Without Antibiotics' Really Means
- FDA Implements Phaseout of Selected Antibiotics
As a result of this antibiotic overuse, bugs have become increasingly resilient, including "strains of drug-resistant tuberculosis and gonorrhea are on the rise," all over the world.
The FDA itself announced in 2013 that it would implement a "guidance document that explains how animal pharmaceutical companies can work with the agency to voluntarily remove growth enhancement and feed efficiency indications from the approved uses of their medically important antimicrobial drug products," but failed to call for the mandatory end of usage of any of these antibiotics.
In an op-ed response, food writer and former New York Times restaurant critic Ruth Reichl called the measures "toothless" and a "blatant failure on food."
Last month, President Obama signed an executive order establishing a new task force to battle drug-resistant infections and develop new antibiotics by 2020, which seems to be the only option left.
Earlier this year, the World Health Organization warmed that, "a post-antibiotic era, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century."
Ms LO, made no mention of Brilacidin, which is owned by Cellceutix (OTCMKTS:CTIX) in her article above. Hopefully she will watch, study and read the soon to released FDA 2b trial results. I believe that they will provide hope of near to intermediate term prescriptions to her desire to avoid the apocalyptic nightmare of a post-antibiotic era.
Shares of Cellceutix involve ultimate risk of principal and should not be considered in the same realm of safety and security, as prudent risk oriented blue chip companies such Dow Chemical, Monsanto, Proctor and Gamble, and Zoetis.
The World Awaits Brilacidin